EMBC Embecta Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1872789 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.6%
TTM net income YoY4.7%
TTM EPS YoY3.5%
Revenue 3-yr CAGR-2.9%
Net income 3-yr CAGR22.8%
Margins
Gross margin59.0%
Operating margin21.9%
Net margin8.6%
FCF margin16.2%
EBITDA margin26.3%
Returns
ROE—
ROA7.2%
ROIC (approx.)26.2%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets148.4%
Debt / equity—
Current ratio1.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.99x
Accruals ratio-7.1%
Payout ratio31.1%
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $271.70M | $221.80M | $261.20M | $264.00M | $295.50M | $259.00M | $261.90M | $286.10M |
| Cost of revenue | $118.40M | $94.00M | $99.50M | $105.50M | $98.40M | $94.90M | $104.80M | $112.30M |
| Gross profit | $153.30M | $127.80M | $161.70M | $158.50M | $197.10M | $164.10M | $157.10M | $173.80M |
| R&D expense | $5.60M | $5.40M | $4.60M | $4.60M | $4.40M | $8.00M | $20.30M | $19.80M |
| SG&A expense | $78.60M | $76.20M | $77.60M | $86.90M | $84.40M | $79.60M | $81.10M | $96.80M |
| Operating income | $48.70M | $35.00M | $83.30M | $56.50M | $94.00M | $62.90M | $28.70M | $26.20M |
| Pretax income | $27.60M | $9.50M | $58.90M | $29.00M | $72.20M | $35.80M | -$700,000 | -$7.00M |
| Income tax | $6.50M | $13.60M | $14.80M | $2.60M | $26.70M | $12.30M | -$700,000 | -$21.60M |
| Net income | $21.10M | -$4.10M | $44.10M | $26.40M | $45.50M | $23.50M | $0 | $14.60M |
| EBITDA | $59.30M | $45.20M | $93.60M | $69.60M | $103.20M | $71.90M | $38.10M | $35.70M |
| EPS (basic) | 0.36 | -0.07 | 0.75 | — | 0.78 | 0.40 | 0.00 | — |
| EPS (diluted) | 0.36 | -0.07 | 0.74 | — | 0.78 | 0.40 | 0.00 | — |
| Dividends declared per share | 0.01 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Weighted avg. shares (diluted) | 58.51M | 59.30M | 59.29M | — | 58.49M | 58.55M | 58.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $214.70M | $184.90M | $201.30M | $225.50M | $233.60M | $212.30M | $216.70M | $274.20M |
| Receivables | $182.20M | $147.10M | $159.20M | $145.60M | $182.80M | $185.60M | $180.90M | $193.00M |
| Inventory | $214.20M | $192.60M | $181.80M | $178.60M | $189.90M | $169.20M | $169.10M | $171.50M |
| Current assets | $705.10M | $608.10M | $620.20M | $631.40M | $681.50M | $643.40M | $667.20M | $761.00M |
| PP&E, net | $316.80M | $237.50M | $248.90M | $257.20M | $262.70M | $257.40M | $258.90M | $290.40M |
| Goodwill | $39.90M | $15.40M | $15.40M | $15.40M | $15.40M | $15.50M | $15.50M | $15.60M |
| Intangibles | $47.50M | $6.50M | $6.70M | $7.00M | $7.30M | $7.60M | $7.90M | $8.10M |
| Total assets | $1.27B | $1.03B | $1.06B | $1.09B | $1.16B | $1.12B | $1.15B | $1.29B |
| Current liabilities | $419.80M | $247.30M | $234.70M | $261.50M | $275.50M | $259.30M | $298.20M | $374.00M |
| Short-term debt | $139.40M | $9.50M | $9.50M | $9.50M | $9.50M | $9.50M | $9.50M | $9.50M |
| Long-term debt | $1.32B | $1.32B | $1.35B | $1.39B | $1.46B | $1.51B | $1.53B | $1.57B |
| Total debt | $1.46B | $1.33B | $1.36B | $1.40B | $1.47B | $1.52B | $1.54B | $1.57B |
| Total liabilities | $1.88B | $1.66B | $1.68B | $1.74B | $1.83B | $1.86B | $1.92B | $2.02B |
| Shareholders' equity | -$612.70M | -$626.10M | -$613.10M | -$650.60M | -$669.60M | -$736.20M | -$768.80M | -$738.30M |
| Net debt | $1.24B | $1.14B | $1.16B | $1.17B | $1.23B | $1.31B | $1.33B | $1.30B |
| Shares outstanding | 56.66M | 59.33M | 59.21M | 58.50M | 58.47M | 58.33M | 58.13M | 57.71M |
| Cash flow statement | ||||||||
| Operating cash flow | $41.80M | $31.10M | $17.20M | $84.00M | $81.20M | $31.80M | -$5.30M | $26.60M |
| Capital expenditure | $1.10M | $500,000 | $600,000 | $7.30M | $400,000 | $100,000 | $1.50M | $0 |
| Free cash flow | $40.70M | $30.60M | $16.60M | $76.70M | $80.80M | $31.70M | -$6.80M | $26.60M |
| Investing cash flow | -$129.50M | -$500,000 | $9.50M | -$7.30M | -$400,000 | -$100,000 | -$1.50M | $0 |
| Financing cash flow | $112.40M | -$41.50M | -$51.60M | -$81.60M | -$62.60M | -$37.30M | -$45.20M | -$36.60M |
| Depreciation & amortization | $10.60M | $10.20M | $10.30M | $13.10M | $9.20M | $9.00M | $9.40M | $9.50M |
| Stock-based compensation | $4.10M | $5.70M | $5.90M | $9.50M | $5.90M | $7.30M | $8.90M | $6.20M |
| Dividends paid | $600,000 | $8.90M | $8.90M | $8.80M | $8.70M | $8.70M | $8.80M | $8.70M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.